Medical technology innovator Neurolief has announced a significant $6 million milestone-based investment from BrainsWay Ltd., a leader in neurostimulation treatments. This crucial funding follows the U.S. Food and Drug Administration's Premarket Approval (PMA) of Neurolief's Proliv™Rx brain neuromodulation system. The investment is poised to accelerate the American rollout of this pioneering at-home therapy for adults whose depression has not adequately improved with antidepressant medication.
Addressing a Critical Gap in Mental Healthcare
A substantial number of adults in the United States live with depression and fail to achieve a sufficient response from initial antidepressant therapies. Although several next-step treatment options are available, their real-world accessibility remains severely limited due to clinic-dependent delivery models. These constraints, combined with infrastructure requirements and referral delays, create logistical barriers that hinder patient uptake and prolong suffering.
A Novel At-Home Neuromodulation Solution
Neurolief's Proliv™Rx system is specifically designed to bridge this critical treatment gap by bringing advanced therapy directly into the patient's home. Having received FDA approval in December 2025, it stands as the first and only prescription brain neuromodulation system for this indication. The device is prescribed and managed by a physician but is self-administered by the patient, ensuring both clinical rigor and unprecedented accessibility.
Strategic Investment to Fuel U.S. Expansion
The investment from BrainsWay is a strong endorsement of Neurolief's mission to democratize access to advanced mental health treatments. Scott Drees, Chief Executive Officer of Neurolief, affirmed that the capital enhances the company's ability to bring clinically validated brain stimulation to more patients. He noted that with FDA approval and early commercial traction, the company is scaling a model built for real-world adoption.
This new care model also aligns with evolving healthcare priorities, as noted by Dr. Owen Muir, Neurolief's Chief Medical Officer. He explained that as health systems move toward value-based care, reaching high-need patients effectively is paramount. Proliv™Rx was developed with this reality in mind, enabling clinicians to expand access and overcome the limitations inherent in facility-based care.
The Companies Behind the Innovation
Neurolief is a neuroscience-driven medical technology company focused on developing non-invasive neuromodulation therapies for mental health and neurological conditions. Its core mission is to combine scientific rigor with scalable, real-world accessibility to bridge critical gaps in patient care. The investment partner, BrainsWay, is a global leader in noninvasive neurostimulation, renowned for its proprietary Deep TMS™ platform technology for various mental health disorders.
The $6 million investment from BrainsWay represents a pivotal step for Neurolief as it prepares to launch its Proliv™Rx system across the United States. This collaboration not only validates the need for accessible mental health solutions but also promises to transform the treatment landscape for millions. By empowering patients to receive advanced, physician-supervised care at home, this initiative marks a hopeful advancement for those with treatment-resistant depression.